Find uplifting stories about heroes, innovations, and solutions
3 results for "bepirovirsen"
For the first time, a new treatment called bepirovirsen has achieved functional cure in 1 in 5 hepatitis B patients, compared to nearly zero with current therapies. This breakthrough could free millions from lifelong daily medication.
An experimental medicine called bepirovirsen achieved functional cures in nearly 20% of chronic hepatitis B patients during clinical trials, a massive leap from current treatments that cure only 1% to 3%. For a disease killing 1 million people annually, this breakthrough could transform millions of lives.
A breakthrough medication called bepirovirsen has functionally cured 20% of chronic hepatitis B patients within one year, marking the first major treatment advance in decades. The FDA is expected to decide on approval this October.